David  Thomson net worth and biography

David Thomson Biography and Net Worth

EVP of MannKind
David joined MannKind after working on the merger that formed the company from three independent biopharma companies. Since January 2002, he has been responsible for its legal and compliance matters. As the longest-serving MannKind employee, David understands the importance of carrying on Al Mann’s legacy of helping people live fuller, healthier lives.

How he lives life more humann:
Outside of the office, David volunteers for the American Youth Soccer Organization (AYSO).

What is David Thomson's net worth?

The estimated net worth of David Thomson is at least $3.34 million as of August 28th, 2023. Mr. Thomson owns 798,835 shares of MannKind stock worth more than $3,339,130 as of April 20th. This net worth estimate does not reflect any other assets that Mr. Thomson may own. Additionally, Mr. Thomson receives an annual salary of $798,530.00 as EVP at MannKind. Learn More about David Thomson's net worth.

How old is David Thomson?

Mr. Thomson is currently 57 years old. There are 8 older executives and no younger executives at MannKind. The oldest executive at MannKind is Mr. John F. Bedard, Senior Vice President of Worldwide Regulatory Affairs, who is 74 years old. Learn More on David Thomson's age.

What is David Thomson's salary?

As the EVP of MannKind Co., Mr. Thomson earns $798,530.00 per year. There are 2 executives that earn more than Mr. Thomson. The highest earning executive at MannKind is Dr. Michael E. Castagna Pharm.D., CEO & Director, who commands a salary of $1,260,000.00 per year. Learn More on David Thomson's salary.

How do I contact David Thomson?

The corporate mailing address for Mr. Thomson and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on David Thomson's contact information.

Has David Thomson been buying or selling shares of MannKind?

David Thomson has not been actively trading shares of MannKind within the last three months. Most recently, David Thomson sold 8,100 shares of the business's stock in a transaction on Monday, August 28th. The shares were sold at an average price of $4.78, for a transaction totalling $38,718.00. Following the completion of the sale, the executive vice president now directly owns 798,835 shares of the company's stock, valued at $3,818,431.30. Learn More on David Thomson's trading history.

Who are MannKind's active insiders?

MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.

Are insiders buying or selling shares of MannKind?

In the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 556,486 shares worth more than $2,496,686.38. The most recent insider tranaction occured on December, 14th when CEO Michael Castagna sold 110,000 shares worth more than $440,000.00. Insiders at MannKind own 3.0% of the company. Learn More about insider trades at MannKind.

Information on this page was last updated on 12/14/2023.

David Thomson Insider Trading History at MannKind

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2023Sell8,100$4.78$38,718.00798,835View SEC Filing Icon  
5/24/2023Sell95,576$4.68$447,295.68735,263View SEC Filing Icon  
8/29/2022Sell7,000$3.67$25,690.00726,035View SEC Filing Icon  
8/27/2021Sell4,100$4.64$19,024.00567,391View SEC Filing Icon  
2/5/2015Sell80,000$7.00$560,000.00View SEC Filing Icon  
11/24/2014Sell118,114$6.14$725,219.96View SEC Filing Icon  
8/7/2014Sell30,000$8.16$244,800.00View SEC Filing Icon  
6/26/2014Sell30,000$10.51$315,300.00View SEC Filing Icon  
6/4/2014Sell133,000$9.95$1,323,350.00View SEC Filing Icon  
12/11/2013Sell150,000$5.00$750,000.0083,752View SEC Filing Icon  
8/28/2013Sell19,204$5.78$110,999.1240,082View SEC Filing Icon  
See Full Table

David Thomson Buying and Selling Activity at MannKind

This chart shows David Thomson's buying and selling at MannKind by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MannKind Company Overview

MannKind logo
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Read More

Today's Range

Now: $4.18
Low: $4.02
High: $4.20

50 Day Range

MA: $4.29
Low: $3.40
High: $5.27

2 Week Range

Now: $4.18
Low: $3.17
High: $5.75

Volume

1,795,644 shs

Average Volume

2,368,819 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28